CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Lucas Montarce

Executive VP & CFO, Lilly (Eli)

Search every verified Lucas Montarce interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Lucas Montarce, Executive Vice President and CFO at Eli Lilly, participated in the company's Q2 2026 earnings call on August 9, 2026. During the call, he commented on the company's financial performance, noting strong results in the first half of the year and an upward revision of the full-year guidance by $2.5 billion. He attributed part of the guidance adjustment to period-over-period changes in estimates for rebates and discounts, which he described as one-offs. Montarce also discussed pricing for the company's product Zepbound, highlighting transparency across various sales channels. He referenced direct-to-patient prices starting at $299 and going up to $449, a bridge program price of $245, and noted that commercial pricing is also part of the overall pricing structure. His remarks focused on explaining the components of the company's pricing and financial outlook.

Recent appearances

Other executives at Lilly (Eli)

  • David Ricks, Chairman, Chief Executive Officer & President

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →